Along with alternative splicing, post-translational modifications and regulatory RNAs, protein multifunctionality is an emerging explanation for the complexity of higher organisms. Protein multifunctionality reduces the need for more protein-coding genes. In addition, expanded functions provide a way to integrate diverse biological systems, by connecting one pathway to another. Prominent among the various examples of multifunctional proteins are members of the aminoacyl tRNA synthetase (AARS) family 1,2 . Although AARSs are well known for their function in activating amino acids for protein synthesis 3 , they also have a broad spectrum of expanded activities in pathways including splicing 4,5 , translational and transcriptional control 6-8 , pro-and antiangiogenesis 9-14 , inflammation 15 , signaling of immune responses 16 , apoptosis 17 and viral assembly 18 . It is these activities that may explain why many tRNA synthetase mutations are associated with disease, especially in instances where the change has no effect on aminoacylation activity [19] [20] [21] [22] [23] . In most cases, however, how and why tRNA synthetases were expropriated for other purposes is still not understood.
a r t i c l e s
Along with alternative splicing, post-translational modifications and regulatory RNAs, protein multifunctionality is an emerging explanation for the complexity of higher organisms. Protein multifunctionality reduces the need for more protein-coding genes. In addition, expanded functions provide a way to integrate diverse biological systems, by connecting one pathway to another. Prominent among the various examples of multifunctional proteins are members of the aminoacyl tRNA synthetase (AARS) family 1,2 . Although AARSs are well known for their function in activating amino acids for protein synthesis 3 , they also have a broad spectrum of expanded activities in pathways including splicing 4,5 , translational and transcriptional control [6] [7] [8] , pro-and antiangiogenesis [9] [10] [11] [12] [13] [14] , inflammation 15 , signaling of immune responses 16 , apoptosis 17 and viral assembly 18 . It is these activities that may explain why many tRNA synthetase mutations are associated with disease, especially in instances where the change has no effect on aminoacylation activity [19] [20] [21] [22] [23] . In most cases, however, how and why tRNA synthetases were expropriated for other purposes is still not understood.
Upon stimulation with the antiproliferative cytokine interferon-γ, the 471-residue human TrpRS is upregulated and secreted from various cell types including endothelial cells 24, 25 . Natural alternative forms of human TrpRS have potent anti-angiogenic activity [9] [10] [11] 14 . This activity is blocked until the N-terminal domain (NTD) is removed, either by alternative splicing to give mini-TrpRS or by proteolysis to give the closely similar T2-TrpRS (composed of residues 94−471 of TrpRS). T2-TrpRS binds to the endothelial cell adherens junction molecule-VE-cadherin 26 -and inhibits activation of genes associated with angiogenesis, such as those encoding AKT and endothelial cell NO synthase 27 . Because it inhibits new blood vessel formation, with no disruption of the existing blood vessels 11, 14 , T2-TrpRS has appeal for therapeutic application, for example, in the treatment of macular degeneration and in oncology 28 .
VE-cadherin, as the main constituent of the adherens junctions of endothelial cells, has a key role in angiogenesis and vascular permeability. The 784-residue molecule has a modular structure consisting of five extracellular cadherin (EC) domains, a single-pass transmembrane α-helix and a cytoplasmic tail that is linked to the cytoskeleton by other protein factors 29 . Endothelial cell-cell adhesion depends on the homophilic interaction between VE-cadherin molecules from neighboring cells, and this homophilic interaction depends on the N-terminal EC domain, known as EC1 (ref. 30; Fig. 1a) . As a type II cadherin, VE-cadherin has two conserved tryptophan residues (Trp2 and Trp4) at positions 2 and 4 from the N terminus. Crystal structures of three different type II cadherin molecules showed that Trp2 and Trp4 are the key determinants for interactions between EC1 domains 31 . Specifically, during dimerization Trp2 and Trp4 from one EC1 domain bind to a large hydrophobic pocket in the other EC1 domain, and vice versa, to lock together the two cadherin molecules 31 (Fig. 1a) . As expected, mutation of either Trp2 or Trp4 disrupts endothelial cell adhesion 32 .
Because a tRNA synthetase specific for tryptophan binds to VE-cadherin, whose function, in turn, depends on two specific tryptophan side chains, we speculated that tryptophan itself is the connection between TrpRS and VE-cadherin. TrpRS, similarly to other members of the tRNA synthetase family, has developed a highly specific amino acid−binding pocket during evolution to prevent misaminoacylation and mistranslation. The active site of TrpRS, which a r t i c l e s binds tryptophan specifically, may be used to bind the Trp2 or Trp4 residue of VE-cadherin. Perhaps it is for this reason that TrpRS was selected, during evolutionary development of complex organisms, to have a function in angiogenesis through its interaction with the VE-cadherin receptor. Using structural modeling, mutagenesis, binding and cell-based functional analyses, we set out to extensively test this hypothesis using human TrpRS and VE-cadherin proteins.
RESULTS

Structural modeling of the TrpRS and VE-cadherin interaction
The previously solved cocrystal structure of human TrpRS bound with tryptophanyl adenylate (Trp-AMP, the reaction intermediate formed in the amino acid activation step) showed in clear detail the tryptophan-binding pocket and the adjacent pocket that holds the AMP moiety 33, 34 . The structure of the EC1 domain of VE-cadherin was built using the homology modeling program Modeller (http://salilab. org/modeller/), using the structures of the EC1 domains of three type II cadherins 31 (MN-cadherin, cadherin-8 and cadherin-11) that share 41-77% sequence identity with EC1 of VE-cadherin. We have modeled the interaction between human T2-TrpRS 35 and VE-cadherin (EC1) (see Online Methods). In the modeled complex, Trp2 of VE-cadherin is bound in the tryptophan-binding pocket of T2-TrpRS, and Trp4 fits well in the pocket for the adenosine moiety of AMP (Fig. 1b) . In part because the tryptophan pocket is deeper relative to the pocket for AMP, the orientation of the two tryptophan residues on VE-cadherin with regard to the two pockets in T2-TrpRS is specific. The rest of the EC1 domain sits on top of, and caps, the active site of T2-TrpRS. Notably, the space occupied by EC1 domain overlaps with the location of the NTD in the crystal structure of full-length (FL) TrpRS (Fig. 1c) . Therefore, EC1 cannot fit into FL-TrpRS because of steric hindrance with the NTD of TrpRS, which blocks access of Trp2 and Trp4 to the active site. This model is consistent with experimental observations that FL-TrpRS is inactive in angiogenesis 9, 11, 14 , and it suggests that this inactivation is attributable to the blocking of the interaction by the NTD.
Binding and functional studies support an inhibitory NTD
To test this model, we first used co-immunoprecipitation to detect binding of FL-TrpRS to VE-cadherin, and we compared the binding with that of T2-TrpRS. For this purpose, we used a fusion of VE-cadherin (extracellular portion) with Fc, which in turn binds to Protein G beads. We incubated FL-TrpRS or T2-TrpRS with VE-cadherin−bound beads. With the same amount of input, the amount of FL-TrpRS that bound to the beads was only about 5% of that of T2-TrpRS (Fig. 2a) . This result suggests specific binding of T2-TrpRS to VE-cadherin and, as expected, a substantially diminished interaction of FL-TrpRS.
We further compared the activity of T2-TrpRS and FL-TrpRS in a tube-formation assay using 3B11 mouse tumor endothelial cells 36 . In this assay, endothelial cells form vessel-like tubes, and formation of these tubes can be blocked by angiostatic factors such as T2-TrpRS. As expected, measurement of the total area covered by the vessels showed that treatment with 2 µM T2-TrpRS for 8 h inhibited tube formation by more than 90%. In contrast, the effect of FL-TrpRS was substantially smaller (Fig. 2b) . These data are consistent with previous studies showing that removal of the NTD is required for activation of the anti-angiogenic activity of TrpRS 9,11,14 .
TrpRS active site involved in receptor binding
TrpRS catalyzes the condensation of tryptophan with ATP to give Trp-AMP. (The adenylate is highly labile, but it is sequestered in the active site to protect it from hydrolysis, before it is condensed with the 3′ end of tRNA to give the aminoacyl tRNA.) A nonhydrolyzable
is a potent inhibitor (of TrpRS) that binds tightly to the active site. Thus, we hypothesized that, if T2-TrpRS does indeed recognize the exposed Trp2 and Trp4 of VE-cadherin through the active site, then either tryptophan or Trp-SA would block the ability of T2-TrpRS to bind to VE-cadherin. The inhibitive capacity of Trp-SA would be expected to be more potent than that of tryptophan: Trp-SA binds more tightly to the active site than does tryptophan, and Trp-SA can block both the tryptophan-and AMP-binding sites, whereas tryptophan can block only the tryptophan-binding site. We found that tryptophan attenuated the binding of T2-TrpRS to VE-cadherin. Moreover, Trp-SA strongly inhibited binding of T2-TrpRS to VE-cadherin in a concentration-dependent manner. In contrast, a noncognate adenylate analog (Met-SA) had no effect (Fig. 3a) . 
r t i c l e s
Notably, using antibodies against the hexahistidine (His 6 ) tag of the recombinant T2-TrpRS, we were able to pull down endogenous VE-cadherin from lysates of bovine aortic endothelial cells. However, if Trp-SA was added to the cell lysate, no VE-cadherin was pulled down; in contrast, addition of Met-SA to the lysate had no effect on the interaction (Supplementary Fig. 1 ). These results support the idea that the tryptophan-binding pocket of T2-TrpRS is essential for binding to VE-cadherin. We also tested the effect of Trp-SA, the strongest known inhibitor of T2-TrpRS binding to VE-cadherin, on the ability of T2-TrpRS to prevent endothelial cell tube formation. Consistent with the previous experiments, T2-TrpRS inhibited tube formation by more than 90%. Addition of Trp-SA to T2-TrpRS reduced the inhibition from 96% to 64%, whereas addition of the noncognate analog Met-SA had no effect. Furthermore, addition of Trp-SA or Met-SA alone, at the same concentration, did not affect tube formation (Fig. 3b) .
Mutational study confirms role of active site
Having established that the active site of T2-TrpRS is important for its interaction with VE-cadherin and its anti-angiogenic activity (as monitored by the tube-formation assay), we next dissected the active site of T2 by mutagenesis. As discussed above, modeling experiments suggested that Trp2 of VE-cadherin binds to the tryptophan-binding pocket and Trp4 binds to the AMP-binding pocket. Thus, guided by our cocrystal structure of TrpRS bound with Trp-AMP (Fig. 4a) , we made four mutants of T2-TrpRS that were expected to disrupt either the tryptophan-or the AMP-binding pocket. In particular, we created the Y159A Q194A TrpRS mutant to disrupt the enzyme's specific recognition of the indole nitrogen of tryptophan. In addition, we created the G161W TrpRS mutant, in which the tryptophan pocket would be blocked by the bulky indole side chain of the tryptophan introduced at position 161. (Fig. 4a) . Using isothermal titration calorimetry (ITC), we found that, whereas wild-type T2-TrpRS bound to tryptophan with a K d of 11 µM (similar to that of FL-TrpRS), Y159A Q194A T2-TrpRS had no detectable association with tryptophan, and G161W T2-TrpRS had a more than 20-fold decreased affinity for tryptophan. We also created two more single mutants-A310W and G172M-in which the AMP pocket is blocked (Fig. 4a) . The weakened binding of these two mutant proteins with AMP was confirmed by equilibrium dialysis (see Online Methods for details).
Next, we carried out co-immunoprecipitation experiments to test the binding of the T2-TrpRS mutants to VE-cadherin. Notably, a r t i c l e s compared to the wild-type protein, all four mutant T2-TrpRSs had substantially diminished binding to VE-cadherin (Fig. 4b) , consistent with the tryptophan and AMP pockets of T2-TrpRS being essential for interaction with VE-cadherin.
We also investigated the functional consequences of the mutations in the endothelial cell tube-formation assay. We prepared the wildtype protein and three mutant proteins (G161W, G172M and A310W) freshly and side by side to ensure that any differences in their activities did not come from sample variability. Although the wild-type T2-TrpRS used in this set of experiments was not as robust as that used in some of the earlier experiments, its angiostatic activity was clear (Fig. 4c) . However, this activity was completely abolished for all three mutant proteins (Fig. 4c) .
The role of Trp2 and Trp4 of VE-cadherin
To investigate the the role of Trp2 and Trp4 in the interaction from the VE-cadherin side, we substituted Trp2 and Trp4 of VE-cadherin to alanine, to create the W2A and W4A VE-cadherin mutants. For this purpose, we used VE-cadherin expressed in HEK 293T cells that had been transfected with a gene encoding either a wild-type or a mutant VE-cadherin−Fc fusion protein. We incubated the transfected HEK 293T cell lysates with T2-TrpRS and, as expected, T2-TrpRS was co-immunoprecipitated with wild-type VE-cadherin. However, the W2A, W4A and W2A W4A VE-cadherin mutants pulled down little or no T2-TrpRS (Fig. 4d) , suggesting that both Trp2 and Trp4 are crucial for the T2-TrpRS interaction, as suggested by our structural model.
To further test the role of Trp4, which is proposed to fit within the adenosine pocket of T2-TrpRS that is adjacent to the tryptophanbinding site (Fig. 4a) , we attempted to create a VE-cadherin mutation of Trp4 that would still accommodate binding of T2-TrpRS. Because the interaction of Trp4 with T2-TrpRS is based on the mutual hydrophobicity of the bulky indole ring of tryptophan and the adenosine pocket of T2-TrpRS, we reasoned that substitution of Trp4 with a bulky hydrophobic residue such as isoleucine would allow interaction of VE-cadherin with T2-TrpRS. (We noted that the fourth position of a type I cadherin is usually an isoleucine residue 29, 31 .) Indeed, the W4I VE-cadherin mutant bound clearly to T2-TrpRS (Fig. 4d) . In contrast, the exact fit of Trp2 within the tryptophan-binding pocket showed little tolerance for a W2I substitution (Fig. 4d) . The specificity of Trp2 reinforced the idea that the T2-TrpRS−VE-cadherin interaction is determined primarily by the precise complementarity between a protruding tryptophan residue of VE-cadherin and a specific tryptophan-binding pocket of T2-TrpRS.
DISCUSSION
As stated above, T2-TrpRS does not affect developed blood vessels ut, instead, blocks development of neovasculature 11, 14 . An interaction between T2-TrpRS and Trp2 and Trp4 of the EC1 domain of VE-cadherin can explain this observation. In normal, existing blood vessels, Trp2 and Trp4 of dimerized VE-cadherin are buried in homophilic interactions between the N-terminal EC1 domains, so they are unable to interact with T2-TrpRS. However, T2-TrpRS can bind to the neovasculature, in which VE-cadherin has not yet engaged in trans-adhesion and, thus, its Trp2 and Trp4 epitopes are fully exposed. As a result, new blood vessel formation cannot occur when T2-TrpRS binds and blocks the crucial Trp2 and Trp4 of VE-cadherin. In support of this concept, previous work showed that a monoclonal anti−VE-cadherin antibody can specifically target the neovasculature because of its ability to bind to Trp2 and Trp4 (ref. 32 ).
There are two types of cadherins-type I and type II. VE-cadherin is a type II cadherin, having two tryptophans (Trp2 and Trp4) near the N terminus. Typically, Trp4 of type II cadherins is replaced by an isoleucine in type I cadherins, whereas Trp2 is conserved in all cadherin molecules 29, 31 . Our mutational study showed that substitution of Trp4 with isoleucine in VE-cadherin did not affect T2-TrpRS binding, suggesting that T2-TrpRS may have a broader specificity beyond VE-cadherin. We tested N-cadherin, a type I cadherin that is found mostly in neurons. Indeed, T2-TrpRS can bind to N-cadherin−Fc (data not shown), suggesting a potentially broad specificity of T2-TrpRS toward the cadherin family, but toward only free cadherin molecules that are not yet involved in cell-cell junctions. Therefore, T2-TrpRS may function as a general inhibitor for cadherin junction−dependent growth.
The catalytic domains of tRNA synthetases have only two known architectures-the Rossmann fold of the class I synthetases and the central β-sheet with flanking α-helices of the class II synthetases. Despite there being only two general architectures, the known expanded functions of tRNA synthetases are mostly idiosyncratic and specific to each synthetase. Thus, those characteristics that are idiosyncratic (that is, unique) to each synthetase may explain the different activities of the different synthetases. One way that idiosyncratic functions can be developed is through acquisitions of appended domains that are specific to the synthetase 6, 12 . Alternatively, new functions may arise from expanded uses of motifs-such as the site for aminoacyl adenylate synthesisoriginally developed for the ancient aminoacylation function. This work demonstrates how the angiostatic function of TrpRS is connected to VE-cadherin through a completely different use of the synthetase's unique local architecture for engaging Trp-AMP. More generally, during evolution and development of the tree of life, in which tRNA synthetases sit at the base, the serendipitous capture of protruding side chains (as substrate mimics) of other proteins may have been the first step in connecting tRNA synthetases with other cellular functions and pathways. 
METHODS
Methods
ONLINE METHODS
Modeling of T2-TrpRS−VE-cadherin complex. First we aligned the VE-cadherin sequence with the sequences of five other homologous type II cadherins (with known crystal structures) using ClustalW 37 . The five type II cadherin crystal structures included human cadherin-8 (EC1−3, PDB 2A62), cadherin-11 (EC1−2, PDB 2A4E), MN-cadherin (EC1, PDB 1ZVN), cadherin-8 (EC1, PDB 1ZXK) and mouse cadherin-11 (EC1, PDB 2A4C) (all structures published in ref. 31) . We then used the alignment and the five structures to model the structure of the EC1 domain of VE-cadherin using Modeller 8v2 (http://salilab.org/modeller/).
For modeling of the complex, we first determined the initial orientation of VE-cadherin EC1 for docking to T2-TrpRS (PDB 1O5T (ref. 35) ) according to the respective global surface electrostatic properties, which were calculated using the Adaptive Poisson-Boltzmann Solver (APBS) package (http://apbs.sourceforge. net/) as a plug-in in PyMol (http://www.pymol.org/). We then manually adjusted the position of the EC1 domain relative to T2-TrpRS to allow its N-terminal end to enter into the Trp-AMP pocket, with the least steric clash for the rest of EC1 domain. We further adjusted the N-terminal D-W2-I-W4 motif to fit into the active site. This initial model was then subject to molecular dynamic refinement in CNS (http://cns-online.org/v1.21/). After refinement, the interaction energy converged at -17,186.937 kcal mol -1 , a value that is indicative of a favorable binding state without any steric clash. The final model of the complex was validated by PROCHECK 38 , with no residues in the disallowed regions of the Ramachandran plot. The coordinates of the complex model and the result of the PROCHECK analysis are included in Supplementary Data 1 and 2.
Endothelial cell tube-formation assay. We performed the tube-formation assay with the mouse endothelial cell line 3B11, using a described protocol 36 .
Preparation of recombinant human T2-TrpRS. We constructed the T2-TrpRS mutants using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Wild-type and mutant T2-TrpRS proteins were expressed in E. coli and purified as described 14 .
Transfection of HEK 293T cells with VE-cadherin constructs. We used wildtype VE-cadherin-Fc cDNA-pCEP4 (a gift from D. M. Shasby 39 ) to make the VE-cadherin mutants. We transfected HEK 293T cells with either wild-type or mutant VE-cadherin−Fc constructs using the Lipofectamine LTX (Invitrogen) kit. After 2 d, the cells were selected for 3 weeks with 10 µg ml -1 blasticidine S (Invitrogen). We used the stably transfected cells to study the interaction between VE-cadherin and T2-TrpRS.
Immunoprecipitation and western blotting. We washed the stably transfected (with various genes for VE-cadherin and its mutants) HEK 293T cells with PBS and extracted cellular proteins in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% (w/v) Triton X-100, 2 mM EDTA and 1× protease inhibitors). The supernatants (0.4 ml) of cell lysates were mixed with equal volumes of either purified T2-TrpRS (10 µg ml −1 ) or lysates of E. coli cells that had been transformed with a gene expressing T2-TrpRS or its mutants. Incubation for 1 h at 4 °C in the presence 5 mM CaCl 2 was followed by incubation with 30 µl of protein G Sepharose for 1 h at 4 °C (with continuous mixing) to allow protein G to capture the VE-cadherin−Fc and T2-TrpRS complex.
To test the effects of agents on the binding of T2-TrpRS to VE-cadherin, we incubated purified human VE-cadherin−Fc (R&D System) with T2-TrpRS and various testing agents, and then incubated the mixture with protein G sepharose.
We analyzed the protein G−bound proteins, after elution with 60 µl of reduced slab gel sample buffer (with a final concentration of 5% (w/v) SDS and 10 mM DTT), by western blotting using rabbit anti−C-terminal human TrpRS and goat anti−human IgG-Fc antibody (Jackson Immuno Research) as primary antibodies to detect T2-TrpRS and VE-cadherin, respectively.
Isothermal titration calorimetry.
We performed ITC at 25 °C using an Omega titration calorimeter (Microcal) as described 40 . Proteins were dialyzed overnight in 20 mM sodium phosphate buffer (pH 7.5) containing 150 mM NaCl, and the final dialysate was used to prepare ligand solutions. Typically, 700 µM of ligand solution was added to 70 µM protein (present in the sample cell, with a volume of 1.34 ml) as a 2-µl injection followed by 30 6-µl injections using a syringe rotating at 400 r.p.m. Between successive injections, an interval of 3 min was allowed so that the baseline could stabilize.
One of the requirements for determining binding constants in an Omega calorimeter is that the C-values should lie between 1 and 1,000, where C = (K a ) × ([M]), with K a as the association constant and [M] as the macromolecule concentration. The experimental conditions ensured that the C-value was always in this range, and the heats obtained from dilution of the ligand were subtracted from the titration data. The data so obtained were fitted via the nonlinear least-squares minimization method to determine binding constants using Origin software (Microcal).
Equilibrium dialysis assay. Because of the low affinity of T2-TrpRS for AMP or ATP 33 , we used an indirect method to evaluate the adenosine pocket of T2-TrpRS mutants (A310W and G172M). We measured tryptophan binding to T2-TrpRS proteins in the presence of the Trp-AMP analog Trp-SA, which acted as a binding inhibitor. A disrupted adenosine pocket would be expected to attenuate the inhibition by Trp-SA. We performed the equilibrium dialysis tryptophan-binding assay using a described method 41 with modifications. Before carrying out the binding experiment, we dialyzed the protein stocks in PBS (pH 7.4). We placed T2-TrpRS or the mutants (20 µM) and [ 14 C]-labeled tryptophan, suspended in PBS, in the two chambers on either side of a semipermeable membrane in the absence or the presence of increasing concentrations of Trp-SA. After overnight dialysis, we measured the radioactivity in both chambers by scintillation counting and used the data to calculate the amounts of free and bound tryptophan at each Trp-SA concentration.
In the absence of Trp-SA, wild-type T2-TrpRS and the A310W and G172M T2-TrpRS mutants have similar affinity for tryptophan (K d is consistent with the number obtained by ITC), and the binding of tryptophan in the absence of Trp-SA was normalized to 100%. As expected, in the presence Trp-SA, tryptophan binding was inhibited (Supplementary Fig. 2) . The inhibition effect with increased Trp-SA concentration was fit with a single-site binding equation y = 100 × (1 − 1/(1 + K I / x)). The inhibition was attenuated for both T2-TrpRS mutants, with stronger attenuation by the A310W mutation than by G172M. This result suggested that the adenosine pocket of T2-TrpRS was disrupted in both mutants and that the degree of disruption was consistent with their disrupted ability to bind VE-cadherin (Fig. 4b) .
